Michael Bogenschutz, MD

Dr. Bogenschutz is the Director of the NYU Langone Center for Psychedelic Medicine, and a Professor of Psychiatry at NYU Grossman School of Medicine. His primary research interest is the development of novel combinations of pharmacologic and psychosocial interventions to treat patients with substance use disorders and other mental health conditions. He began conducting clinical research with psychedelics in 2011, and has published extensively on topics related to psychedelics and addiction. He published the first contemporary pilot study of psilocybin-assisted therapy for alcohol use disorder in 2016, and he recently completed a randomized controlled trial of psilocybin-assisted therapy for AUD. On the strength of those findings, he is now continuing that line of research as the Lead Investigator of a large multisite RCT of psilocybin for AUD, sponsored by B.More. He is also the NYU site PI for MAPS-sponsored phase II and III trials of MDMA-assisted psychotherapy for PTSD, is conducting NIH-funded studies of cannabidiol and topiramate for AUD and PTSD, and is developing further clinical and mechanistic studies of psychedelics such as psilocybin and MDMA. Before joining the faculty of NYU in 2015, he was the Principal Investigator of the Southwest Node of the NIDA Clinical Trials Network and a Professor at the University of New Mexico Health Sciences Center, where he was Vice-Chair and Division Director for Addiction Psychiatry, and Vice Chair for Clinical Research in the Department of Psychiatry.